RxDoctor Payments Data

Chad Winters, DO

Family Medicine · Lenexa, KSNPI 1710942891

Payments from drug & device makers

$10,066in general payments, 2019–2025

Across 641 payments — averaging $15.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • Pfizer$1K
  • Lilly USA, LLC$728
  • AstraZeneca$565
  • Boehringer Ingelheim$525
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$10,048100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)79$1,307
Novo Nordisk74$1,185
Pfizer82$1,007
Lilly USA, LLC42$728
AstraZeneca39$565
Boehringer Ingelheim32$525
Amgen30$502
GSK22$317
Amarin Pharma, Inc.21$310
Merck16$230
Teva Pharmaceuticals USA, Inc.13$227
Johnson & Johnson14$213
Novartis13$202
Takeda Pharmaceuticals U.S.A., Inc.12$172
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC10$171
Kowa Pharmaceuticals America, Inc.11$161
Boston Scientific2$141
E.r. Squibb & Sons, L.L.C.8$141
Abbott7$139
Lundbeck LLC5$101
Upsher-smith Laboratories LLC6$100
Biohaven Pharmaceutical Holding Company Ltd.5$94
IBSA Pharma Inc.5$92
Otsuka America Pharmaceutical, Inc.4$83
Gilead5$79
Currax Pharmaceuticals LLC6$79
Astellas Pharma US Inc5$68
Sanofi-aventis U.S. LLC4$62
Biohaven Pharmaceuticals, Inc.4$62
Phathom Pharmaceuticals, Inc.4$60
Collegium Pharmaceutical, Inc.5$58
Ardelyx, Inc.3$54
Scilex Pharmaceuticals Inc.4$54
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$50
Avanir Pharmaceuticals, Inc.3$43
Supernus Pharmaceuticals, Inc.3$38
Organogenesis Inc.1$37
Sanofi Pasteur Inc.2$34
Ironwood Pharmaceuticals, Inc2$31
Bayer2$28
Neurocrine Biosciences, Inc.1$25
Medtronic2$24
Zyla Life Sciences, Inc.2$24
Amneal Pharmaceuticals LLC1$23
Neurelis, Inc.1$21
Mylan Pharmaceuticals Inc.1$21
Nestle Healthcare Nutrition Inc.1$20
Sunovion Pharmaceuticals Inc.1$19
Neos Therapeutics, LP1$19
Esperion Therapeutics, Inc.1$19
Shionogi Inc1$18
Cequr Corporation1$18
Axsome Therapeutics, Inc.1$17
Vanda Pharmaceuticals Inc.1$16
Circassia Inc.1$16
Agile Therapeutics, Inc.1$15
Bausch Health US, LLC1$14
Neuronetics, Inc.1$14
Agios Pharmaceuticals, Inc.1$14
Adlon Therapeutics L.p.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,066 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$58,537
Medicare patients
257
Services billed
1,082

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban101$91,918
JardianceEmpagliflozin66$77,832
OzempicSemaglutide56$61,860
MounjaroTirzepatide27$39,267
FarxigaDapagliflozin Propanediol40$34,918
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$26,082
XareltoRivaroxaban29$23,967
MyrbetriqMirabegron13$9,016
Breo ElliptaFluticasone/Vilanterol18$6,590
Tresiba Flextouch U-200Insulin Degludec11$6,580
Rosuvastatin Calcium356$5,524
SymbicortBudesonide/Formoterol Fumarate12$5,433
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$3,848
Atorvastatin Calcium486$3,799
Valsartan128$2,980

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,007$91,918101 claims
Boehringer IngelheimJardiance$525$77,83266 claims
Novo NordiskOzempic$1,185$61,86056 claims
AstraZenecaFarxiga, Symbicort$565$40,35052 claims
Lilly USA, LLCMounjaro$728$39,26727 claims
GSKTrelegy Ellipta, Breo Ellipta$317$32,67345 claims
Johnson & JohnsonXarelto$213$23,96729 claims
Astellas Pharma US IncMyrbetriq$68$9,01613 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$23$2,315276 claims
AbbVieSynthroid$1,307$1,79413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Lenexa

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →